BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?
Adaptive Immunity
BCG Vaccine
/ administration & dosage
Betacoronavirus
/ immunology
COVID-19
COVID-19 Vaccines
Clinical Trials as Topic
Coronavirus Infections
/ epidemiology
Humans
Immunization, Secondary
Mass Vaccination
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Viral Vaccines
Antigen specific immunity
BCG
COVID-19
HCW
Immune response
Revaccination
Journal
Allergologia et immunopathologia
ISSN: 1578-1267
Titre abrégé: Allergol Immunopathol (Madr)
Pays: Singapore
ID NLM: 0370073
Informations de publication
Date de publication:
Historique:
received:
21
05
2020
revised:
24
05
2020
accepted:
28
05
2020
pubmed:
13
7
2020
medline:
6
10
2020
entrez:
13
7
2020
Statut:
ppublish
Résumé
The impact of COVID-19 is changing with country wise and depend on universal immunization policies. COVID-19 badly affects countries that did not have universal immunization policies or having them only for the selective population of countries (highly prominent population) like Italy, USA, UK, Netherland, etc. Universal immunization of BCG can provide great protection against the COVID-19 infection because the BCG vaccine gives broad protection against respiratory infections. BCG vaccine induces expressions of the gene that are involved in the antiviral innate immune response against viral infections with long-term maintenance of BCG vaccine-induced cellular immunity. COVID-19 cases are reported very much less in the countries with universal BCG vaccination policies such as India, Afghanistan, Nepal, Bhutan, Bangladesh, Israel, Japan, etc. as compared to without BCG implemented countries such as the USA, Italy, Spain, Canada, UK, etc. BCG vaccine provides protection for 50-60 years of immunization, so the elderly population needs to be revaccinated with BCG. Several countries started clinical trials of the BCG vaccine for health care workers and elderly people. BCG can be uses as a prophylactic treatment until the availability of the COVID-19 vaccine.
Identifiants
pubmed: 32653224
pii: S0301-0546(20)30106-3
doi: 10.1016/j.aller.2020.05.002
pmc: PMC7332934
pii:
doi:
Substances chimiques
BCG Vaccine
0
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
507-517Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.
Références
Curr Clin Top Infect Dis. 1995;15:253-70
pubmed: 7546371
J Infect Dis. 2013 Apr;207(7):1084-94
pubmed: 23293360
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Leukoc Biol. 2005 Jul;78(1):106-13
pubmed: 15845642
Eur J Immunol. 2015 Apr;45(4):1159-69
pubmed: 25529558
J Immunol. 2006 Oct 15;177(8):5647-51
pubmed: 17015753
Adv Virus Res. 2019;105:93-116
pubmed: 31522710
J Leukoc Biol. 2018 Apr;103(4):739-748
pubmed: 29345365
Clin Infect Dis. 2004 Sep 1;39(5):652-7
pubmed: 15356778
Front Immunol. 2017 Apr 05;8:407
pubmed: 28424703
J Hosp Infect. 2016 Mar;92(3):235-50
pubmed: 26597631
J Virol. 2002 Sep;76(17):8729-36
pubmed: 12163593
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
JAMA. 1994 Mar 2;271(9):698-702
pubmed: 8309034
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Thorax. 2001 Sep;56(9):741-2
pubmed: 11563362
Trends Mol Med. 2013 Dec;19(12):705-13
pubmed: 24138818
Vaccine. 2015 Oct 5;33(41):5470-5474
pubmed: 26275478
Cold Spring Harb Perspect Med. 2014 Jun 02;4(6):
pubmed: 24890836
Clin Vaccine Immunol. 2010 Oct;17(10):1500-6
pubmed: 20685935
J Infect Dis. 2015 Dec 15;212(12):1930-8
pubmed: 26071565
Ann N Y Acad Sci. 2005 Dec;1062:69-78
pubmed: 16461790
JAMA. 2004 May 5;291(17):2086-91
pubmed: 15126436
Infect Immun. 2000 Dec;68(12):6883-90
pubmed: 11083809
Clin Microbiol Infect. 2019 Dec;25(12):1473-1478
pubmed: 31055165
Clin Infect Dis. 2000 Sep;31 Suppl 3:S64-7
pubmed: 11010824
J Clin Invest. 2018 May 1;128(5):1837-1851
pubmed: 29461976
J Virol. 2013 Oct;87(20):11160-7
pubmed: 23926349
J Immunol. 2008 Dec 1;181(11):7948-57
pubmed: 19017986
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
PLoS Pathog. 2015 Oct 06;11(10):e1005206
pubmed: 26440518
Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7
pubmed: 9526191
Immunology. 1999 Aug;97(4):573-81
pubmed: 10457209
J Mol Med (Berl). 2005 Mar;83(3):180-92
pubmed: 15635478
Infect Control Hosp Epidemiol. 2002 Oct;23(10):591-4
pubmed: 12400888
Nat Immunol. 2000 Nov;1(5):398-401
pubmed: 11062499
J Mol Biol. 2014 Mar 20;426(6):1246-64
pubmed: 24316048
J Infect Dis. 1977 Aug;136(2):171-5
pubmed: 894076
Semin Immunol. 2013 Apr;25(2):172-81
pubmed: 23706597
Front Immunol. 2017 Sep 13;8:1134
pubmed: 28955344
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Mol Immunol. 2019 May;109:58-70
pubmed: 30856410
J Virol. 2005 Sep;79(18):11892-900
pubmed: 16140765
J Infect Dis. 2007 Sep 15;196(6):853-60
pubmed: 17703415
J Pediatr (Rio J). 2006 Jul;82(3 Suppl):S45-54
pubmed: 16826312
PLoS Med. 2011 Mar;8(3):e1001012
pubmed: 21445325
Microbes Infect. 2006 Apr;8(5):1339-46
pubmed: 16697232
Front Immunol. 2019 May 29;10:1144
pubmed: 31191528
Nat Biotechnol. 2012 Dec;30(12):1210-6
pubmed: 23159882
AMA Arch Intern Med. 1958 May;101(5):881-93
pubmed: 13519929